SHJBF (Shanghai Junshi Biosciences Co) Current Deferred Revenue: $0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHJBF Shanghai Junshi Biosciences Co Ltd SHJBF
68 GF Score
Price $3.35
GF Value $5.38
! 4 Warning Signs
View Full Analysis

What is Shanghai Junshi Biosciences Co Current Deferred Revenue?

Shanghai Junshi Biosciences Co SHJBF +11.67% 68 Current Deferred Revenue is $0.0 Mil as of Dec. 2025. GuruFocus rates SHJBF with a GF Score™ of 68/100 and a GF Value™ of $5.38. The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Shanghai Junshi Biosciences Co's current deferred revenue for the quarter that ended in Dec. 2025 was $0.0 Mil.

Shanghai Junshi Biosciences Co Current Deferred Revenue Related Terms

Shanghai Junshi Biosciences Co Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Shanghai Junshi Biosciences Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Junshi Biosciences Co Current Deferred Revenue Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Shanghai Junshi Biosciences Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHJBF
68GF Score
Shanghai Junshi Biosciences Co Ltd SHJBF
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.0 Mil mean?
Shanghai Junshi Biosciences Co (SHJBF) has a Current Deferred Revenue of $0.0 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Shanghai Junshi Biosciences Co and its competitors.
Is Shanghai Junshi Biosciences Co's Current Deferred Revenue too high?
Shanghai Junshi Biosciences Co's current Current Deferred Revenue is $0.0 Mil. Overall, Shanghai Junshi Biosciences Co has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Junshi Biosciences Co's Current Deferred Revenue compare to VRTX and REGN?
Shanghai Junshi Biosciences Co's Current Deferred Revenue of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Shanghai Junshi Biosciences Co and its competitors. Shanghai Junshi Biosciences Co's current Current Deferred Revenue is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Junshi Biosciences Co stock overvalued right now?
Shanghai Junshi Biosciences Co (SHJBF) has a current Current Deferred Revenue of $0.0 Mil. The stock's GF Value™ is $5.38, compared to a current price of $3.35 — trading 37.7% below its estimated fair value. The current Current Deferred Revenue is $0.0 Mil. Shanghai Junshi Biosciences Co's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Shanghai Junshi Biosciences Co (SHJBF), the current Current Deferred Revenue is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Junshi Biosciences Co (SHJBF) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued. The current stock price of $3.35 is trading 37.7% below its estimated GF Value™ of $5.38.

Key valuation signals for SHJBF:

  • Current Deferred Revenue: $0.0 Mil
  • GF Value™: $5.38 vs. price of $3.35 (37.7% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the SHJBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Junshi Biosciences Co Business Description

Other Exchanges 01877:Hong Kong688180:China
Address No. 987 Cai Lun Road, Level 4, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
68GF Score

Get the complete analysis for SHJBF

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.35
Price
$5.38
GF Value